WiCON | Pharma China (Web Edition)

WiCON International Group
21 Bridge Street
Metuchen, NJ 08840, USA
Tel/Fax: +1 801-751-5728
info@pharmachinaonline.com

Affiliated Companies
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com

BJ Jicai PharmTech
Oriental Kenzo Plaza
Beijing, China
Tel: +86 10 84476010
info@pharmachinaonline.com

China Adopts Patent Law Amendment: A Game Changer for Innovative Drugs Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with emphasis on latest developments on the Chinese IP landscape, in particular the new...
(11/2/2020)

Contract Pharma: Bye-Bye China? (11/18/2020)

WSJ: Chinese Covid Vaccine Gives Scientists Pa... (11/18/2020)

Bloomberg: Pfizer Seeks Deals With Chinese Bio... (11/18/2020)

What to Expect in China's 14th Five Year Plan?... (11/13/2020)

Bloomberg: China Under Pressure to Reveal Covi... (11/12/2020)

Facing The Chinese Challenge – Are Indian Pha... (11/11/2020)

FiercePharma: Ten Biotechs to Know in China (11/11/2020)

Abbvie Aims to Boost Innovation and Drug Devel... (11/9/2020)

Three Considerations for Businesses in China W... (11/9/2020)

Nature: Trends in Oncology Drug Innovation in ... (11/9/2020)

Recent Official and Executive Moves (11/27/2020) Xbiome Raises Over $14M in Series B Fina... (11/27/2020) CDE Solicits Comments on the Technical G... (11/27/2020) Financial-related Company News in Brief (11/27/2020) NMPA and Chinese Customs Announce Additi... (11/26/2020) China Issues the Working Plan for Innova... (11/26/2020) Antengene Granted Chinese Approval for P... (11/25/2020) Sinopharm Seeking Chinese Approval for C... (11/25/2020) (Free) Snapshot of MNC China Performance in 3Qs... (11/25/2020) Snapshot of BMI System Financial Perform... (11/25/2020) NHSA Makes Advances on National Medical ... (11/25/2020) Performance Snapshot of A Share-Listed C... (11/25/2020) Sales Expenditure Far Exceeds R&D Spendi... (11/25/2020) CDE Issues the CDE Guidelines for Manage... (11/25/2020) Basilea and Pfizer Files NDA for Antifun... (11/24/2020) Alvotech, CCHT and Yangtze River Pharma... (11/24/2020)

SMEI Releases H1/2020 Chinese Drug Market Data by Termi... Snapshot of Urban Chinese Retail Pharmacy Chemical Drug... Snapshot of Urban Chinese Public Medical Institution Ch... Review of Chemical Drug Sales in Chinese Urban Public H... Snapshot of Cardiovascular Drug Sales in Chinese Urban ...

Financial-related Company News in Brief Xbiome Raises Over $14M in Series B Financing Sales Expenditure Far Exceeds R&D Spending at A Share-l... Performance Snapshot of A Share-Listed Chinese MedPharm... Snapshot of MNC China Performance in 3Qs/2020 and New P...

CDE Solicits Comments on the Technical Guidelines for C... China Issues the Working Plan for Innovative Developmen... NMPA and Chinese Customs Announce Addition of Two Drug ... CDE Issues the CDE Guidelines for Management of Supplem... CDE Solicits Comments on Two Draft Documents for Phase ...

NHSA Makes Advances on National Medical Insurance IT In... Snapshot of BMI System Financial Performance in 3Qs/202... NHSA Issues New Documents on Big Data Diagnosis-Interve... NHSA Issues Two Drug Price and Tender Purchase Credit R... Hainan Lecheng Expands Its Global Special Drug Insuranc...

Genscript Chairman Arrested on Suspected Smuggling Offe... Wanbangde Pharma Fined CNY 2.5M for Abuse of Market Mon... SAMR Releases Draft Anti-Monopoly Rules To Scrutinize O... The Supreme People's Court Solicits Public Comments on ... Hogan Lovells: China Adopts Revised Patent Law with Hat...

India Probes Alleged API Dumping by Chinese Companies China Increases Prices of Key Drug Ingredients by Up To... U.S. Introduces A 'Buy American First' Pharma Executive... Fitch: No Near-Term Impact on Chinese API Makers as Pha... Indian Firms Challenged by API Price Hikes by Chinese S...

Sinopharm Seeking Chinese Approval for COVID-19 Vaccine Antengene Granted Chinese Approval for Phase I/II Trial... Ascentage Approved for Two PIb/II Trials of the Bcl-2 ... Basilea and Pfizer Files NDA for Antifungal Cresemba in... Onconova Files IND for Multi-kinase CDK4/6 Inhibitor i...

BioAtla and BeiGene Revise Global Deal for Novel Condit... Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ...

Recent Official and Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves Recent Executive Moves

Upcoming Event: Plenareno Pharma Middle East Virtual Co... Live Podcast - VC & Impact Investing in China: Investin... 2020 Fall/Winter Promotion - Pharma China publications USTR Satisfied with China's Implementatin of Phase 1 US... U.S.-China ESRC Hearing: China's Evolving Healthcare Sy...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

Pharma China on Twitter and Faceboo... WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON to Hold Pharma China Annual F... WiCON Publishes the China Pharmaceu...